tesamorelin for hiv lipodystrophy: Frequently asked questions

Administer the missed dose as soon as you remember on the same day, then resume your regular schedule the following day. If you miss an entire day, skip that dose and continue the next day. Do not double-dose to compensate. The half-life of tesamorelin is under one hour, so missing a single dose does not result in loss of treatment effect, but missing doses regularly (more than 2–3 per week) reduces the cumulative GH exposure needed to sustain lipolysis in visceral adipocytes. Patients in the pivotal trials who maintained at least 80% adherence achieved the full VAT reduction observed in the primary analysis.

A fasting glucose above 126 mg/dL on two separate occasions meets the diagnostic threshold for diabetes and requires immediate prescriber consultation. In the pivotal trials, patients who developed new-onset diabetes were discontinued from tesamorelin, and glucose levels normalized within 4–8 weeks of stopping. The prescriber may reduce the dose temporarily, add metformin to improve insulin sensitivity, or discontinue tesamorelin if the glucose elevation persists. Growth hormone opposes insulin action in skeletal muscle and adipose tissue, so the diabetogenic effect is mechanism-based and predictable. This is why baseline HbA1c and fasting glucose screening is mandatory before starting therapy.

Any temperature excursion above 8°C for more than 2 hours risks protein denaturation. The peptide structure unfolds irreversibly, losing biological activity even if the solution appears visually unchanged. Unreconstituted lyophilised tesamorelin is more stable and can tolerate brief ambient temperature exposure (up to 25°C for 24–48 hours), but once mixed with bacteriostatic water, the reconstituted peptide must remain refrigerated at 2–8°C. If you suspect a cold chain break, contact the supplying pharmacy. Most compounding facilities replace temperature-compromised vials at no charge if reported within 48 hours. There is no home test for potency, so visual inspection (cloudiness, discoloration, particulate matter) is the only practical check, though these signs appear only after severe degradation.

VAT will reaccumulate to near-baseline levels within 26 weeks of discontinuation in most patients, as demonstrated in the COSMIX extension trial. This is not a medication failure. It reflects the fact that tesamorelin corrects a growth hormone deficiency caused by ongoing antiretroviral therapy, and the deficiency returns when the GHRH signal is removed. Patients who wish to stop can transition to intensive lifestyle modification (caloric deficit, resistance training) to slow reaccumulation, but the metabolic benefit of tesamorelin is conditional on continued use. Some prescribers trial a reduced maintenance dose (1mg daily instead of 2mg) after initial VAT reduction, though this approach is not protocol-based and lacks clinical trial validation.

Recheck fasting glucose and HbA1c within 2 weeks. If fasting glucose remains >126 mg/dL on repeat testing or HbA1c increases by >0.5% from baseline, discontinue tesamorelin and consult your prescribing physician. The glucose elevation is a direct pharmacological effect of increased IGF-1 impairing peripheral insulin sensitivity. Dose reduction does not mitigate this risk. Most patients see glucose normalize within 4–8 weeks of stopping. If VAT reduction is clinically necessary, an endocrinologist may recommend metformin or other insulin sensitizers before attempting to restart at a lower frequency (e.g., 5 days per week instead of 7).

No. Administer the missed dose as soon as you remember within the same 24-hour period, then resume your regular schedule the following evening. If more than 24 hours have passed, skip the missed dose entirely and continue with the next scheduled injection. Doubling the dose disrupts the pulsatile GH rhythm tesamorelin is designed to mimic and increases the risk of hyperglycemia, joint pain, and fluid retention. Missing occasional doses reduces cumulative VAT reduction but does not negate prior progress. Consistency over weeks matters more than perfection on individual days.

First, verify adherence: are you injecting nightly without missed doses? Second, confirm storage integrity. Has the medication been maintained at 2–8°C continuously, including during reconstitution and between pharmacy delivery and home refrigeration? Third, request waist circumference measurement and DEXA scan or CT imaging to quantify VAT objectively. Patient perception of abdominal fat does not correlate reliably with visceral adiposity. If all of the above are confirmed and imaging shows <5% VAT reduction at 12 weeks, you may be a non-responder (seen in approximately 15–20% of patients). Possible mechanisms include genetic variations in GHRH receptor density, concurrent medications that suppress GH secretion (e.g., glucocorticoids), or advanced hepatic steatosis blunting GH responsiveness.

Contact your prescriber immediately for glucose monitoring and risk-benefit reassessment, but do not discontinue without guidance. Growth hormone is a counter-regulatory hormone that opposes insulin, so modest glucose elevations (5–10 mg/dL fasting glucose increase) are common and expected. If HbA1c remains below 6.5% and fasting glucose stays under 110 mg/dL, continuation with monthly monitoring is often appropriate. However, if you develop fasting glucose consistently above 126 mg/dL or HbA1c above 6.5%, your provider may recommend discontinuation or initiation of metformin to manage emerging insulin resistance. The FDA black-box warning exists because uncontrolled hyperglycemia poses greater long-term risk than the cardiovascular benefit of VAT reduction. Each case requires individualized risk stratification.

No. VAT rebound occurs predictably within 6–12 months of stopping tesamorelin. The TRIM extension data showed near-complete reversal of VAT reduction when patients discontinued after 26 weeks, confirming that tesamorelin's metabolic effect is active treatment-dependent, not a durable reset of adipocyte metabolism or fat partitioning. If you wish to maintain reduced visceral fat, indefinite daily administration is required. Some patients and providers explore maintenance strategies like reduced dosing frequency (every other day) or intermittent treatment cycles, but no controlled trial data support these approaches. They represent off-label experimentation.

Ask your provider whether your abdominal fat distribution qualifies as lipodystrophy and whether baseline CT imaging to quantify visceral adipose tissue would be appropriate. Many HIV specialists reserve Egrifta for patients with documented excess VAT (typically ≥130 cm² at L4–L5 on CT) rather than subjective clinical assessment alone, because the metabolic and cardiovascular risks correlate with visceral depot size, not total body weight or waist circumference. If your provider is unfamiliar with Egrifta, request referral to an HIV metabolic specialist or endocrinologist experienced in lipodystrophy management. Tesamorelin prescribing requires familiarity with growth hormone physiology, glucose monitoring protocols, and realistic outcome expectations.

Technically yes, though insurance coverage will almost certainly be denied, and cost becomes prohibitive at $4,500+ per month out-of-pocket. Off-label prescribing of tesamorelin for general visceral obesity or metabolic syndrome occurs occasionally in concierge or anti-aging practices, but it lacks evidence-based support. The Phase 3 NAFLD trial in non-HIV patients showed liver fat reduction but did not result in FDA approval, and no trials have evaluated cardiovascular outcomes in general populations. GLP-1 receptor agonists (semaglutide, tirzepatide) produce superior total weight loss with weekly dosing and broader insurance coverage for obesity indications, making them more practical first-line options for non-HIV patients seeking metabolic improvement.

Injection site reactions (erythema, pruritus, induration) occur in 35–40% of patients initially but typically resolve by week 4–6 as the immune system acclimates to the peptide. Persistent reactions beyond 8 weeks suggest either contaminated reconstitution technique or an allergic response to the peptide itself. Switch to a fresh box of vials stored correctly, ensure you're using sterile water (not bacteriostatic water, which contains benzyl alcohol that some patients react to), and confirm the needle gauge is 27G or finer. If reactions persist despite technique correction, discontinue and consult your prescriber. True peptide allergy is rare but prohibits further use.

Reassess three variables: injection technique, dietary carbohydrate intake, and baseline IGF-1 response. If IGF-1 hasn't increased by at least 50 ng/mL from baseline, the peptide isn't triggering sufficient GH release. This occurs in 10–15% of patients and suggests pituitary hyporesponsiveness that won't improve with higher doses. If IGF-1 has risen appropriately but VAT remains stable, the issue is energy balance: tesamorelin stimulates lipolysis, but if caloric intake (especially refined carbohydrates) drives de novo lipogenesis at an equal or greater rate, net VAT remains unchanged. Reducing daily carbohydrate intake to under 150g while maintaining the protocol typically restarts VAT reduction within 4–6 weeks.

No. Never double-dose tesamorelin. The peptide's mechanism depends on mimicking natural GH pulsatility, and a 4mg dose would create a supra-physiological spike that increases glucose intolerance risk without additional VAT reduction. If you miss a dose by fewer than 12 hours, administer it as soon as you remember and continue the regular schedule the next day. If more than 12 hours have passed, skip the missed dose entirely and resume at the usual time. Missing 2–3 doses per month reduces cumulative VAT reduction by approximately 8–12% at 26 weeks based on adherence subset analysis from the COSMIX trial.

Check the temperature indicator strip included with the shipment. If it shows temperature exceeded 8°C, contact the supplier immediately for replacement. Tesamorelin exposed to temperatures above 8°C for extended periods (>24 hours) experiences irreversible denaturation that neither appearance nor reconstitution behavior will reveal. Even if the peptide dissolves normally and appears clear, receptor binding affinity may be reduced by 20–40%, producing inconsistent results. Real Peptides includes temperature monitoring on every shipment and replaces any package that exceeded thermal specifications during transit at no cost, because peptide integrity is non-negotiable for reliable research outcomes.

Tesamorelin's efficacy depends on functional pituitary somatotrophs capable of responding to GHRH stimulation. In models with constitutively elevated GH (pituitary adenomas, acromegaly models), additional GHRH stimulation produces minimal incremental GH increase because GH negative feedback via IGF-1 and somatostatin has already downregulated GHRH receptor density. Baseline GH and IGF-1 measurement before initiating tesamorelin protocols is essential to establish receptor responsiveness. If baseline IGF-1 is >300 ng/mL (substantially above physiological range), expect attenuated response. The Phase 3 trials specifically enrolled patients with normal baseline GH function, not GH-excess states.

The clinical trials used a fixed 2mg daily dose regardless of body weight (participants ranged from 55kg to 110kg) and achieved consistent VAT reduction across weight categories, suggesting the dose-response relationship plateaus at 2mg. Lower doses (1mg daily) were tested in Phase 2 and produced approximately 60% of the VAT reduction seen at 2mg. Not a proportional response. Doses above 2mg did not increase VAT reduction but did increase adverse events (injection site reactions, peripheral edema). For research models with substantially different body mass or metabolic rate than humans, consider dose scaling by body surface area rather than weight: human equivalent dose calculation is (animal dose mg/kg) × (animal Km / human Km), where Km is a species-specific correction factor.

Discard the vial immediately and do not administer. Properly reconstituted tesamorelin should be clear and colorless. Cloudiness or visible particles indicate aggregation, which occurs when peptide tertiary structure denatures and proteins clump together. Aggregated peptides lose receptor binding activity and can trigger immune responses in vivo. This typically results from one of three errors: injecting bacteriostatic water too forcefully onto the powder (shear force), using water warmer than 4°C for reconstitution, or allowing the lyophilized powder to reach room temperature before adding water. Always reconstitute cold peptide with cold water, inject slowly against the vial wall, and allow 2–3 minutes of undisturbed dissolution.